Effect of Iressa with/without concurrent chemoradiotherapy on tumor gene expression profiles in patients with advanced non-nasopharyngeal head and neck carcinoma

Study identifier:1839IL/0547

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase II study of Iressa with/without concurrent chemoradiotherapy in patients with advanced non-nasopharyngeal head and neck carcinoma and to study the effect of Iressa™ (ZD1839) on tumour gene expression profiles ®

Medical condition

head and neck cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Gefitinib

Sex

All

Actual Enrollment

60

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jun 2004
Primary Completion Date: -
Study Completion Date: 01 Dec 2005

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2007 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria